BroadenBio’s HPK1 Inhibitor Selected for Poster Presentation in AACR 2023

On April 4, 2023 BroadenBio reported the company will present the preclinical data of BB3008 will be presented in the poster session on April 19, 2023 (Poster, BroadenBio, APR 4, 2023, View Source [SID1234640203]). The information has been published on the AACR (Free AACR Whitepaper) official website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Detailed Information

Title: BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models

Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3

Session Date and Time: Wednesday Apr 19, 2023 9:00 AM – 12:30 PM

Location: Poster Section 35

Poster Board Number: 15

Abstract Presentation Number: LB324

About AACR (Free AACR Whitepaper)

The American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting is one of the largest worldwide academic conferences on international cancer research. The conference focuses on the latest progress in various fields of cancer research, releases innovative target research, preclinical data and early clinical trial results, and promotes exchanges and cooperation among cancer researchers around the world. The 2023 annual meeting will be held at the Orange County Convention Center in Orlando, Florida, U.S. from April 14 to 19, 2023.